1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor

Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor

  1. Calliope
    CNS & neurological disorders drug targets, 2006, Vol.5(4), pp.445-52

    Wood, Martyn D ; Scott, Claire ; Clarke, Kirsten ; Cato, Katherine J ; Patel, Nisha ; Heath, Jennie ; Worby, Angela ; Gordon, Laurie ; Campbell, Lorraine ; Riley, Graham ; Davies, Ceri H ; Gribble, Andrew ; Jones, Declan N C

    Abstract
    Antipsychotic drugs (APD) are widely prescribed for the treatment of schizophrenia. The APD are differentiated into typical and atypical based on the lower incidence of extra-pyramidal side-effects associated with the newer atypical APD. It was suggested that atypicality may arise from an interaction with the 5-hydroxytryptamine (5HT)(2) receptor and specifically on the 5-HT(2):dopamine D2 affinity ratio. It is now realised that multiple subtypes of these receptors exist and that in addition, atypical APD interact with many monoamine receptors. The aim of the present study was to characterise the interaction of APD with a variety of monoamine receptors in terms of both affinity and efficacy. The data produced has highlighted that the atypical profile of APD such as olanzapine and clozapine may reflect antagonism of the 5-HT2A and 5-HT2C receptors, whilst that of, ziprasidone and quetiapine may reflect partial agonist activity at the 5-HT1A receptor, and that of aripiprazole may reflect partial agonist activity at the 5-HT1A receptor as well as is its claimed partial agonist activity at the dopamine D2 receptor.